SNOA Stock Forecast: Sonoma Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 21 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Sonoma Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (93): Sales and profits are climbing, and climbing faster than before.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SNOA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SNOA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Sept 2023 | Ladenburg Thalmann | Initiates | Buy | $3.25 |
| 25 Nov 2020 | Benchmark | Initiates | Speculative Buy | — |
| 25 Nov 2020 | Maxim Group | Downgrade | Hold | — |
| 6 Mar 2018 | Maxim Group | Downgrade | Hold | — |
| 28 Dec 2017 | Benchmark | Initiates | Speculative Buy | — |
| 10 Nov 2017 | Maxim Group | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
SNOA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SNOA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Sonoma Pharmaceuticals, Inc. returned −77.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SNOA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.2×
- Price / book
- 0.6×
- EV / EBITDA
- —
Cheaper than 91% of US stocks
Cheaper than 83% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 40.2%
- Operating margin
- −3.3%
- Net margin
- −7.6%
Higher than 50% of US stocks
Higher than 31% of US stocks
Higher than 22% of US stocks
- Return on equity
- −34.5%
- Return on assets
- −3.1%
- Dividend yield
- —
Higher than 26% of US stocks
Higher than 35% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sonoma Pharmaceuticals, Inc. has a market value of $4.1M and an enterprise value of $91K.
Revenue in the twelve months to 30 June 2026: $21.9M. The latest quarter grew 59.6% year on year.
Net income over the same four quarters: −$2.3M, a −10.3% net margin.
Free cash flow in the twelve months to 30 June 2026: −$2.7M.
Sonoma Pharmaceuticals, Inc. employs 10 people — $2.2M of revenue per employee.
Data provided by Twelve Data
SNOA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SNOA’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Sonoma Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SNOA
How does Ticker Nerd's model rank SNOA?
As at 21 Nov 2026, Sonoma Pharmaceuticals, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).
What is the SNOA stock forecast for 2030?
No analyst covering Sonoma Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNOA are extrapolating price history, which says nothing about the business.
How has SNOA stock performed over the past year?
Sonoma Pharmaceuticals, Inc. returned -77.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sonoma Pharmaceuticals, Inc. do?
Sonoma Pharmaceuticals Inc. is a healthcare company that develops and manufactures stabilized hypochlorous acid (HOCl) products used across wound care, eye care, oral and nasal care, dermatology, podiatry, animal health, and non-toxic disinfection. Its portfolio is built around topical and cleansing solutions designed for sensitive skin and tissue, supporting clinicians and patients in managing irritation, infection risk, and recovery in both medical and consumer settings.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals Inc. is a healthcare company that develops and manufactures stabilized hypochlorous acid (HOCl) products used across wound care, eye care, oral and nasal care, dermatology, podiatry, animal health, and non-toxic disinfection. Its portfolio is built around topical and cleansing solutions designed for sensitive skin and tissue, supporting clinicians and patients in managing irritation, infection risk, and recovery in both medical and consumer settings. Sonoma Pharmaceuticals markets its products internationally through healthcare and specialty channels, with applications spanning acute and chronic care environments as well as veterinary uses. The company also focuses on advanced tissue care and other topical formulations, making it a niche participant in the broader pharmaceutical and medical products market. Sonoma Pharmaceuticals Inc. is headquartered in Boulder, Colorado.
CEO Ms. Amy M. Trombly Esq., J.D. · 10 employees · United States · https://sonomapharma.com